XoNovo Overview

  • Founded
  • 2013
  • Status
  • Private
  • Latest Deal Type
  • Accelerator/​Inc
  • Investors
  • 1

XoNovo General Information


Developer of technologies for the treatment of neurodegenerative diseases. The company develops a candidate drug which targets a protein implicated in several neurodegenerative diseases, including alzheimer's disease and batten disease.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Other Devices and Supplies
Other Industries
Drug Discovery
Primary Office
  • 3422 Old Capitol Trail
  • Suite 700
  • Wilmington, DE 19808
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

XoNovo Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Accelerator/Incubator 14-Jan-2015 Completed Startup
To view XoNovo’s complete valuation and funding history, request access »

XoNovo Executive Team (4)

Name Title Board Seat Contact Info
Liora Wiksman Chief Executive Officer
Kenneth Hensley Co-Founder & Chief Scientific Officer
Ofir Levi Co-Founder
Rafi Gidron Ph.D Co-Founder & Chairman
To view XoNovo’s complete executive team members history, request access »

XoNovo Board Members (1)

Name Representing Role Since
Rafi Gidron Ph.D Self Co-Founder & Chairman 000 0000
To view XoNovo’s complete board members history, request access »

XoNovo Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
FutuRx Accelerator/Incubator 000 0000 000000 0
To view XoNovo’s complete investors history, request access »